Drugging the pain epigenome
Authors:
- 26 May 2017
- journal article
- review article
- Published by Springer Nature in Nature Reviews Neurology
- Vol. 13 (7) , 434-447
Abstract
More than 20% of adults worldwide experience different types of chronic pain, which are frequently associated with several comorbidities and a decrease in quality of life. Several approved painkillers are available, but current analgesics are often hampered by insufficient efficacy and/or severe adverse effects. Consequently, novel strategies for safe, highly efficacious treatments are highly desirable, particularly for chronic pain. Epigenetic mechanisms such as DNA methylation, histone modifications and microRNAs (miRNAs) strongly affect the regulation of gene expression, potentially for long periods over years or even generations, and have been associated with pathophysiological pain. Several studies, mostly in animals, revealed that inhibitors of DNA methylation, activators and inhibitors of histone modification and modulators of miRNAs reverse a number of pathological changes in the pain epigenome, which are associated with altered expression of pain-relevant genes. This epigenetic modulation might then reduce the nociceptive response and provide novel therapeutic options for analgesic therapy of chronic pain states. However, a number of challenges, such as nonspecific effects and poor delivery to target cells and tissues, hinder the rapid development of such analgesics. In this Review, we critically summarize data on epigenetics and pain, focusing on challenges in clinical development as well as possible new approaches to the drug modulation of the pain epigenome.Keywords
This publication has 192 references indexed in Scilit:
- HDAC inhibitors attenuate the development of hypersensitivity in models of neuropathic painPain, 2013
- Selective targeting of ASIC3 using artificial miRNAs inhibits primary and secondary hyperalgesia after muscle inflammationPain, 2011
- Bidirectional integrative regulation of Cav1.2 calcium channel by microRNA miR‐103: role in painThe EMBO Journal, 2011
- Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myelomaCancer, 2010
- Multiple roles of HDAC inhibition in neurodegenerative conditionsTrends in Neurosciences, 2009
- Genome-wide Mapping of HATs and HDACs Reveals Distinct Functions in Active and Inactive GenesCell, 2009
- CpG islands – ‘A rough guide’FEBS Letters, 2009
- DNA methylation in ES cells requires the lysine methyltransferase G9a but not its catalytic activityThe EMBO Journal, 2008
- Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabineInternational Journal of Cancer, 2008
- Chromatin Modifications and Their FunctionCell, 2007